Gaidzik et al. [10] compared 53 mutant RUNX1 and 831 wild-type RUNX1 newly-diagnosed AML patients, and found inferior rates of event-free survival (EFS), relapse-free survival (RFS), and overall survival (OS) in RUNX1-mutated patients in patients 60 years of age or younger and treated with intensive chemotherapy (EFS, 8% vs. 30%; RFS, 26% vs. 44%; OS, 32% vs. 45%). This evidence concerns the gene RUNX1 and acute myeloid leukemia.